Compare ADMA Biologics Inc (ADMA) vs Marathon Digital Holdings Inc (MARA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Marathon Digital Holdings Inc — how do they compare? ADMA Biologics Inc trades at $10.16 (market cap $2.28B), while Marathon Digital Holdings Inc trades at $9.25 (market cap $3.65B). The key difference: Marathon Digital Holdings Inc is the larger of the two by market cap, and Marathon Digital Holdings Inc is more actively traded (20,632,567 versus 1,627,324). Which is the better fit depends on your goals — on Pluang, investors hold ADMA Biologics Inc for 18 Days and Marathon Digital Holdings Inc for 22 Days on average.
| ADMA | MARA | |
|---|---|---|
Market Cap | $2.28B | $3.65B |
Volume | 1,627,324 | 20,632,567 |
Sector | Health | Financials |
52-Week High | $20.38 | $22.84 |
52-Week Low | $7.60 | $6.73 |
Typical Hold Time | 18 Days | 22 Days |
Enterprise Value | $2.35B | $5.69B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA Biologics trades at $10.36 with modest daily gains of 0.29%. The stock shows strong profitability with 32.98% net margins and robust ROE of 41.9%. Recent earnings performance has been mixed with two misses in the last three quarters. Technical indicators suggest a bullish trend while oscillators remain neutral. Analyst consensus is strongly positive with 90% buy ratings and an $18.67 price target representing 80% upside potential.
The investment case hinges on ADMA's strong fundamentals and analyst optimism, though recent legal investigations and earnings volatility present risks. The significant gap between current price and analyst targets suggests substantial upside if the company can maintain its profitability trajectory and resolve legal concerns. Execution on upcoming Q3 earnings will be critical for near-term direction.
Marathon Digital Holdings (MARA) trades at $9.65, down 2.62% on the day, with a bearish technical signal despite some bullish oscillators. The company shows concerning fundamentals with a net income margin of -429.71% and negative cash flow from operations of $802.73 million in 2025. Recent earnings have consistently missed expectations, though analyst consensus remains mixed with a $13.00 price target representing 35% upside potential.
While MARA trades at attractive valuation multiples (P/E 3.37, EV/EBITDA 3.31), the company faces significant profitability challenges and cash burn. The stock's performance remains heavily tied to Bitcoin sentiment, creating volatility risks. Analyst coverage shows equal buy/hold recommendations, suggesting uncertainty about near-term recovery prospects amid ongoing operational losses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Marathon Digital Holdings Inc
Marathon Digital Holdings, Inc. is one of the largest publicly traded Bitcoin mining companies in North America. The company focuses on building and operating large-scale, cost-efficient Bitcoin mining facilities. Marathon's strategy centers on increasing its mining hash rate and using sustainable energy sources to expand its Bitcoin production. The company's performance is closely tied to the price of Bitcoin and the overall health of the digital asset mining industry.
Read more on MARA →
